查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1969266

水痘天皰瘡市場：按藥物類別、給藥途徑、治療線和最終用戶分類 - 全球預測 2026-2032

Bullous pemphigoid Market by Drug Class, Route Of Administration, Therapy Line, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，水痘天皰瘡市場價值將達到 3.7975 億美元，到 2026 年將成長至 4.0244 億美元，到 2032 年將達到 5.7414 億美元，年複合成長率為 6.08%。

主要市場統計數據
基準年 2025 3.7975億美元
預計年份：2026年 4.0244億美元
預測年份 2032 5.7414億美元
複合年成長率 (%) 6.08%

水痘天皰瘡的簡明臨床和策略概述：病理生理學、未滿足的醫療需求、不斷發展的治療方法以及相關人員的優先事項。

水痘天皰瘡是一種常見的自體免疫水痘疾病，主要影響老年人，其特徵是由針對半橋粒蛋白的自身抗體引起的表皮下水痘形成。臨床症狀差異很大，從局部搔癢性皮疹到廣泛性張力性水痘，並伴隨繼發性感染的風險，嚴重影響患者的功能狀態和生活品質。診斷通常包括臨床評估（含直接螢光檢查）、BP180和BP230自體抗體檢測以及組織病理學檢查，以與其他水痘疾病鑑別。

水痘天皰瘡的診斷、臨床實踐模式和治療創新正在發生變革性變化：跨越醫療保健機構和學科。

近年來，水痘天皰瘡的診斷路徑、治療策略制定和診療模式都發生了變革性變化。免疫診斷技術的進步以及臨床醫生對自身抗體譜的深入理解，降低了診斷的不確定性。同時，更新的指引也越來越強調長期治療中減少荷爾蒙用量的重要性。此外，生物目標製劑的臨床證據和真實世界經驗促使人們重新評估其獲益風險，並為長期高劑量糖皮質激素治療提供了替代方案。

美國計劃於 2025 年實施的關稅調整預計將對供應鏈、採購、價格壓力和跨境物流產生累積影響。

美國提案的2025年關稅調整可能會影響藥品供應鏈、採購慣例和價格談判。進口藥品原料藥、生物製藥成分或成品的關稅增加，可能會推高製造商和合約製造商的投入成本，促使他們重新評估供應商組合。為此，各企業可能會考慮將生產轉移到近岸地區、實現原料藥來源多元化，並簽訂長期供應契約，以穩定投入成本並降低海關延誤帶來的風險。

依治療領域分類的策略資訊：治療分類、給藥途徑、通路、終端用戶趨勢、對治療線的影響。

水痘天皰瘡的細分市場趨勢反映了多種因素的複雜交互作用，包括藥物類別特徵、給藥便利性、分銷能力、終端使用者需求以及在治療方案中的定位。藥物類別包括生物製藥、糖皮質激素和免疫抑制劑。在生物製藥中，Omalizumab和Rituximab等藥物備受關注；在糖皮質激素中，Methylprednisolone和潑尼松是常用藥物；免疫抑制劑包括Azathioprine、胺基甲基葉酸和Mycophenolate Mofetil。這些藥物類別在研發複雜性、監測要求和耐受性方面存在顯著差異，這些差異會影響臨床導入和醫保支付方的評估。

從地理觀點比較不同地區的醫療服務模式、報銷環境、監管考量和創新採納。

區域差異顯著影響水痘天皰瘡的臨床路徑、治療途徑和治療起始曲線。在美洲，醫療保健系統將完善的專科診所網路與先進的靜脈輸液技術相結合，而支付方也越來越要求簽訂基於真實世界證據和療效的契約，以支持高成本治療。這種環境有利於那些能夠減少住院次數和類固醇相關併發症的治療方法，並支持大規模的專科藥房基礎設施，以提供患者支持和藥物依從性計畫。

以研發、夥伴關係模式、供應鏈韌性和專業服務提供為特徵的公司的策略行動和競爭定位。

水痘天皰瘡領域的競爭動態受多種企業類型和策略行動的影響。創新生物製藥公司專注於開發平臺，旨在拓展標靶治療的適應症，並產生可靠的療效比較證據。同時，學名藥和生物相似藥生產商則優先考慮生產擴充性、成本效益，並競標來滿足長期以來對皮質類固醇和傳統免疫抑制劑的需求。

為高階主管、醫療保健領導者、支付方和銷售團隊提供個人化、可操作的建議，從而加快採用速度、改善治療效果並控制成本波動。

產業領導者應推動一系列合作行動，將臨床創新轉化為以患者為中心的永續醫療服務。首先，透過供應商多角化、策略性庫存管理和短期生產夥伴關係，投資提升價值鏈韌性，可以降低關稅和物流中斷帶來的風險。其次，建構包含隨機對照試驗數據和可操作的註冊研究結果的可靠證據包，將有助於加強與支付方的價值對話，並爭取更有利的報銷條款。

概述了可靠的調查方法，包括資料來源、相關人員訪談、證據整合、檢驗程序和分析嚴謹性。

本分析所依據的研究採用了混合方法，以確保方法的嚴謹性和實際應用價值。主要資料收集包括對皮膚科醫生、醫院藥劑師、專科診所管理人員、支付方和供應鏈主管進行結構化訪談，以了解相關人員對診斷、治療選擇、採購和獲取障礙的觀點。次要資訊包括同行評審的臨床文獻、治療指南、監管文件和公共聲明，以驗證臨床和監管背景。

全面整合，為臨床、商業和政策決策者提取關鍵見解、策略意義和前瞻性觀點。

本篇綜述重點關注水痘天皰瘡治療和商業領域的動態變化，其促進因素包括臨床上對減少類固醇暴露的需求、生物目標成熟的循證醫學證據以及醫療保健總成本面臨的系統性壓力。診斷技術的進步、醫療服務模式的演變以及專業分銷管道的拓展，為相關人員提供了展現實際價值和營運準備的機會。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章水痘天皰瘡市場：依藥物類別分類

  • 生物製藥
    • Omalizumab
    • Rituximab
  • 皮質類固醇
    • Methylprednisolone
    • 強的松
  • 免疫抑制劑
    • Azathioprine
    • 胺基甲基葉酸
    • Mycophenolate Mofetil

第9章：水痘天皰瘡市場：依給藥途徑

  • 靜脈注射
  • 口服
  • 外用

第10章水痘天皰瘡市場依治療方案分類

  • 一線治療
  • 維持治療
  • 二級治療

第11章水痘天皰瘡市場：依最終使用者分類

  • 居家醫療設施
  • 醫院
    • 私立醫院
    • 公立醫院
  • 專科診所
    • 皮膚科診所
    • 門診部

第12章水痘天皰瘡市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章水痘天皰瘡市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章水痘天皰瘡市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國水痘天皰瘡市場

第16章：中國水痘天皰瘡市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Argenx SE
  • AstraZeneca plc
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline plc
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
Product Code: MRR-535C62918796

The Bullous pemphigoid Market was valued at USD 379.75 million in 2025 and is projected to grow to USD 402.44 million in 2026, with a CAGR of 6.08%, reaching USD 574.14 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 379.75 million
Estimated Year [2026] USD 402.44 million
Forecast Year [2032] USD 574.14 million
CAGR (%) 6.08%

A concise clinical and strategic overview of bullous pemphigoid outlining pathophysiology, unmet care gaps, evolving treatments, and stakeholder priorities

Bullous pemphigoid represents a prevalent autoimmune blistering condition primarily affecting older adults, characterized by subepidermal blister formation driven by autoantibodies against hemidesmosomal proteins. Clinically, the disease ranges from localized pruritic eruptions to widespread tense bullae with secondary infection risk and significant impacts on functional status and quality of life. Diagnosis typically involves clinical assessment supported by direct immunofluorescence, autoantibody testing for BP180 and BP230, and histopathology to differentiate it from other blistering disorders.

Therapeutic management has historically relied on systemic and topical corticosteroids to control inflammation and arrest blister formation, but long-term steroid exposure carries substantial morbidity in the aging patient population. Consequently, treatment approaches have evolved toward steroid-sparing strategies that prioritize immunosuppressants and, more recently, targeted biologic therapies. These shifts stem from an expanding evidence base, a greater emphasis on patient-centered outcomes, and an imperative to reduce adverse event burden for frail patients.

Across clinical and payer stakeholders, the disease presents multiple care gaps: delayed diagnosis, variability in treatment intensity, limited access to specialty dermatology services in some regions, and uneven reimbursement frameworks for high-cost therapies. These challenges create both clinical urgency and strategic opportunity for organizations that can offer safer, efficacious therapeutic options, integrated care models, and pragmatic access solutions that address the needs of older, comorbid patients.

Transformative shifts reshaping diagnosis, clinical practice patterns, and therapeutic innovation in bullous pemphigoid across care settings and specialty disciplines

Recent years have witnessed transformative shifts across diagnostic pathways, therapeutic decision making, and care delivery models for bullous pemphigoid. Advances in immunodiagnostics and broader clinician familiarity with autoantibody profiles have reduced diagnostic ambiguity, while guideline updates increasingly emphasize steroid-sparing regimens for long-term management. Concurrently, clinical evidence and real-world experience with targeted biologics have reweighted benefit-risk assessments, offering alternatives to chronic high-dose corticosteroid therapy.

Beyond clinical innovation, health-system dynamics are evolving: payers and providers are more actively judging treatments by total cost of care, adverse event avoidance, and hospitalization reduction. This orientation favors therapies that can demonstrably reduce steroid-associated complications and downstream utilization. At the same time, telemedicine and distributed care pathways have expanded follow-up capabilities for older patients, enabling earlier recognition of flares and improved adherence monitoring.

Commercially, these shifts are catalyzing new partnership models between specialty pharmacies, manufacturers, and provider networks aimed at streamlining access and patient support. Evidence generation strategies are becoming more sophisticated, combining controlled clinical trials with pragmatic studies and registries to capture outcomes relevant to regulators and payers. Taken together, these forces are repositioning bullous pemphigoid from a steroid-dominated paradigm toward a diversified therapeutic landscape that prioritizes safety, durability, and real-world effectiveness.

Anticipated cumulative effects of United States tariff changes in 2025 on supply chains, procurement, pricing pressures, and cross-border logistics

Proposed tariff adjustments in the United States for 2025 carry implications that extend into pharmaceutical supply chains, procurement practices, and pricing negotiations. Increased duties on imported active pharmaceutical ingredients, biologic components, or finished products can amplify input costs for manufacturers and contract producers, prompting reassessments of supplier portfolios. In response, organizations are likely to consider nearshoring of manufacturing, diversification of API sourcing, and longer-term supply agreements to stabilize input costs and mitigate exposure to customs delays.

These supply-side adaptations can cascade into distribution and procurement behavior. Health systems and hospital pharmacies may increase inventory buffers for critical therapies to avoid shortages, while specialty distributors could renegotiate terms to absorb volatility. For high-cost biologic therapies, where manufacturing scale and cold-chain logistics are critical, tariff-driven cost pressures may accentuate the importance of efficient downstream distribution and consolidated shipping models. Conversely, generic corticosteroids and conventional immunosuppressants, which often rely on commodity APIs, may experience increased price sensitivity in procurement tenders.

Payers and contracting teams will respond by tightening value-based purchasing criteria and reinforcing outcome-based agreements where possible. Manufacturers should therefore prioritize transparent cost modeling, supply-chain visibility, and collaborative contracting to preserve access. In addition, regulatory authorities and customs administrations will remain focal points for operational risk management, and proactive stakeholder engagement will help organizations navigate tariff-related friction while protecting continuity of care.

Segment-level strategic intelligence on therapeutic classes, administration routes, distribution channels, end-user dynamics, and therapy line implications

Segment-level dynamics in bullous pemphigoid reflect a complex interplay between drug class characteristics, administration convenience, distribution capabilities, end-user needs, and therapy line positioning. Drug class segmentation includes biologics, corticosteroids, and immunosuppressants; within biologics, therapeutic attention is centered on agents such as omalizumab and rituximab, while corticosteroids commonly involve methylprednisolone and prednisone, and the immunosuppressant category encompasses azathioprine, methotrexate, and mycophenolate mofetil. These classes differ markedly in development complexity, monitoring requirements, and tolerability profiles, which in turn influence clinical adoption and payer assessment.

Route-of-administration segmentation spans intravenous, oral, and topical modalities, with intravenous administration often linked to biologic deployment and requiring infusion infrastructure, whereas oral and topical options support broader ambulatory and home-based management. Distribution channel segmentation ranges from hospital pharmacy through online pharmacy to retail pharmacy, with online models further divided into B2B and B2C platforms that offer differentiated access and fulfillment capabilities. End-user segmentation captures homecare settings, hospitals, and specialty clinics; hospitals are further divided into private and public facilities, while specialty clinics include dermatology clinics and outpatient clinics, each with distinct referral patterns and capacity constraints.

Therapy-line segmentation defines first-line, maintenance, and second-line roles, shaping both clinical decision making and commercial positioning. First-line strategies frequently emphasize rapid disease control with manageable safety profiles, maintenance strategies prioritize durability and tolerability, and second-line interventions are reserved for refractory disease or steroid-intolerant patients. Cross-segmentally, uptake drivers include safety and efficacy evidence, route-of-administration convenience, distribution readiness, and payer reimbursement policies, with each factor exerting differential influence depending on the therapeutic and care setting involved.

Geographic perspectives that compare care delivery patterns, reimbursement landscapes, regulatory considerations, and innovation adoption across regions

Regional differences materially shape clinical pathways, access mechanisms, and adoption curves for bullous pemphigoid therapies. In the Americas, health systems combine robust specialty clinic networks with advanced infusion capacity, and payers increasingly demand real-world evidence and outcomes-based contracting to support high-cost interventions. This environment favors therapies that demonstrate reductions in hospitalizations and steroid-related complications and supports sizable specialty pharmacy infrastructure for patient support and adherence programs.

In Europe, Middle East & Africa, the regulatory landscape is heterogeneous, with European regulatory harmonization fostering centralized approvals while Middle Eastern and African markets experience variable access due to differing reimbursement frameworks and supply-chain constraints. Regional centers of dermatology excellence tend to lead clinical adoption, and public hospitals often play a key role in procurement decisions, making pricing negotiations and health-technology assessments central to access outcomes.

In Asia-Pacific, demographic trends toward aging populations increase clinical burden and demand for scalable care models. Diverse payer systems coexist with rapidly developing private sector capabilities and growing digital health adoption that supports remote monitoring and follow-up. Manufacturing capacity in some Asia-Pacific countries also presents opportunities for regional sourcing and localized supply resilience. Across all regions, cross-border logistics, regulatory alignment, and local clinical practice patterns determine the speed and extent of therapeutic uptake, and these factors should inform regional go-to-market strategies.

Corporate strategic behaviors and competitive positioning that highlight R&D focus, partnership models, supply chain resilience, and specialty service offerings

Competitive dynamics in bullous pemphigoid are shaped by several corporate archetypes and strategic behaviors. Innovative biopharmaceutical companies focus on R&D pipelines that expand indications for targeted therapies and generate robust comparative-effectiveness evidence. Generics and biosimilar manufacturers emphasize scalable production, cost-efficiency, and tender participation to address long-standing corticosteroid and conventional immunosuppressant demand.

Specialty pharmacies and integrated distribution partners are increasingly central to commercial execution, providing patient support programs, adherence monitoring, and complex logistics management that are particularly important for biologics requiring cold-chain handling. Contract development and manufacturing organizations play a pivotal role in enabling rapid scale-up and in diversifying supply across geographies to mitigate tariff and geopolitical risk. Diagnostics and laboratory service providers contribute by advancing autoantibody testing capabilities and enabling earlier, more precise diagnosis.

Strategically, leading organizations pursue collaborations that blend clinical expertise, payer-facing evidence generation, and channel optimization. Examples include co-investment in registries, outcome-based contracting pilots with payers, and partnerships with telehealth providers to enhance post-discharge monitoring. These approaches reduce time-to-adoption, address payer concerns about long-term value, and create differentiated service propositions that extend beyond product labels.

Actionable recommendations tailored for executives, medical leaders, payers, and commercial teams to accelerate adoption, improve outcomes, and manage cost dynamics

Industry leaders should pursue a set of coordinated actions to convert clinical innovation into sustainable, patient-centered access. First, investing in supply-chain resilience through supplier diversification, strategic inventory management, and near-term manufacturing partnerships will reduce exposure to tariff and logistics disruptions. Second, building robust evidence packages that combine randomized data with pragmatic registry-based outcomes will strengthen value conversations with payers and support favorable reimbursement terms.

Third, aligning commercial models with specialty pharmacy and integrated care networks will streamline patient onboarding, adherence support, and safety monitoring-particularly for biologic therapies delivered intravenously or requiring complex handling. Fourth, prioritizing patient support programs that address the unique needs of older adults, such as transportation assistance and simplified dosing regimens, will improve retention and real-world outcomes. Fifth, pursuing outcome-based contracting and risk-sharing pilots with payers can de-risk access to high-cost therapies and demonstrate commitment to measurable value.

Finally, embracing digital tools-telemedicine for follow-up, digital registries for longitudinal outcomes, and remote monitoring platforms-will enhance real-world data capture and support continuous quality improvement. Taken together, these actions provide a pathway to accelerate adoption while managing cost and preserving patient safety.

Robust research methodology overview describing data sources, stakeholder interviews, evidence synthesis, validation steps, and analytical rigor

The research underpinning this analysis used a mixed-methods approach to ensure methodological rigor and practical relevance. Primary data collection included structured interviews with dermatologists, hospital pharmacists, specialty clinic managers, payers, and supply-chain executives to capture stakeholder perspectives on diagnosis, treatment preferences, procurement, and access barriers. Secondary sources comprised peer-reviewed clinical literature, treatment guidelines, regulatory documents, and public policy statements to triangulate clinical and regulatory context.

Evidence synthesis involved iterative cross-validation of findings across sources, with thematic analysis applied to qualitative interviews to surface emerging trends and strategic priorities. Validation steps included expert review by clinical and commercial advisors and scenario testing to assess the robustness of qualitative conclusions under alternative supply-chain and reimbursement environments. The research also acknowledged limitations related to regional heterogeneity in clinical practice and the evolving evidence base for newer biologic therapies, and it therefore emphasized adaptive strategies rather than prescriptive forecasts.

Ethical considerations and data governance protocols guided primary research activities, ensuring anonymization of interview responses and adherence to applicable data-protection norms. The methodology aimed to balance depth of insight with breadth of stakeholder representation to deliver practical, defensible conclusions for decision makers.

Closing synthesis that distills critical insights, strategic implications, and future-facing considerations for clinical, commercial, and policy decision makers

This synthesis brings into focus a therapeutically and commercially dynamic landscape for bullous pemphigoid, driven by clinical imperatives to reduce steroid exposure, by the maturing evidence base for targeted biologics, and by system-level pressures on total cost of care. Diagnostic improvements, evolving care delivery models, and the proliferation of specialty distribution channels create opportunities for stakeholders that can demonstrate real-world value and operational readiness.

At the same time, external pressures such as tariff changes, supply-chain volatility, and regional regulatory diversity require proactive mitigation strategies, including supplier diversification, outcome-focused contracting, and investment in regional capabilities. Successful actors will combine scientific rigor with operational excellence, integrating clinical evidence, payer engagement, and specialty distribution to enable sustainable access.

In closing, the pathway to improved outcomes for patients with bullous pemphigoid lies in coordinated action across clinical development, commercial strategy, and supply-chain design. Organizations that adopt a holistic, evidence-driven approach will be best positioned to translate therapeutic innovation into consistent, equitable care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Bullous pemphigoid Market, by Drug Class

  • 8.1. Biologics
    • 8.1.1. Omalizumab
    • 8.1.2. Rituximab
  • 8.2. Corticosteroids
    • 8.2.1. Methylprednisolone
    • 8.2.2. Prednisone
  • 8.3. Immunosuppressants
    • 8.3.1. Azathioprine
    • 8.3.2. Methotrexate
    • 8.3.3. Mycophenolate Mofetil

9. Bullous pemphigoid Market, by Route Of Administration

  • 9.1. Intravenous
  • 9.2. Oral
  • 9.3. Topical

10. Bullous pemphigoid Market, by Therapy Line

  • 10.1. First Line
  • 10.2. Maintenance
  • 10.3. Second Line

11. Bullous pemphigoid Market, by End User

  • 11.1. Homecare Settings
  • 11.2. Hospitals
    • 11.2.1. Private Hospitals
    • 11.2.2. Public Hospitals
  • 11.3. Specialty Clinics
    • 11.3.1. Dermatology Clinics
    • 11.3.2. Outpatient Clinics

12. Bullous pemphigoid Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Bullous pemphigoid Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Bullous pemphigoid Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Bullous pemphigoid Market

16. China Bullous pemphigoid Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AbbVie Inc.
  • 17.6. Argenx SE
  • 17.7. AstraZeneca plc
  • 17.8. Bristol-Myers Squibb Company
  • 17.9. Eli Lilly and Company
  • 17.10. F. Hoffmann-La Roche AG
  • 17.11. GlaxoSmithKline plc
  • 17.12. Novartis AG
  • 17.13. Pfizer Inc.
  • 17.14. Regeneron Pharmaceuticals, Inc.
  • 17.15. Sanofi S.A.
  • 17.16. Sun Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BULLOUS PEMPHIGOID MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BULLOUS PEMPHIGOID MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY THERAPY LINE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA BULLOUS PEMPHIGOID MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY OMALIZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY OMALIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY OMALIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY RITUXIMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY RITUXIMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY RITUXIMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY METHYLPREDNISOLONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY METHYLPREDNISOLONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY METHYLPREDNISOLONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY PREDNISONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY PREDNISONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY PREDNISONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY AZATHIOPRINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY AZATHIOPRINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY AZATHIOPRINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY METHOTREXATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY METHOTREXATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY METHOTREXATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY MAINTENANCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY MAINTENANCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY MAINTENANCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY DERMATOLOGY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY DERMATOLOGY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY DERMATOLOGY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA BULLOUS PEMPHIGOID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA BULLOUS PEMPHIGOID MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA BULLOUS PEMPHIGOID MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA BULLOUS PEMPHIGOID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA BULLOUS PEMPHIGOID MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA BULLOUS PEMPHIGOID MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE BULLOUS PEMPHIGOID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE BULLOUS PEMPHIGOID MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE BULLOUS PEMPHIGOID MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST BULLOUS PEMPHIGOID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST BULLOUS PEMPHIGOID MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST BULLOUS PEMPHIGOID MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC BULLOUS PEMPHIGOID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC BULLOUS PEMPHIGOID MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC BULLOUS PEMPHIGOID MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN BULLOUS PEMPHIGOID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN BULLOUS PEMPHIGOID MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN BULLOUS PEMPHIGOID MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 172. GCC BULLOUS PEMPHIGOID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. GCC BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 174. GCC BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 175. GCC BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 176. GCC BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 177. GCC BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 178. GCC BULLOUS PEMPHIGOID MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 179. GCC BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. GCC BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 181. GCC BULLOUS PEMPHIGOID MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION BULLOUS PEMPHIGOID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION BULLOUS PEMPHIGOID MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION BULLOUS PEMPHIGOID MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS BULLOUS PEMPHIGOID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS BULLOUS PEMPHIGOID MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS BULLOUS PEMPHIGOID MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 202. G7 BULLOUS PEMPHIGOID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. G7 BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 204. G7 BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 205. G7 BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 206. G7 BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 207. G7 BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 208. G7 BULLOUS PEMPHIGOID MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 209. G7 BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. G7 BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 211. G7 BULLOUS PEMPHIGOID MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 212. NATO BULLOUS PEMPHIGOID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 213. NATO BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 214. NATO BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 215. NATO BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 216. NATO BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 217. NATO BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 218. NATO BULLOUS PEMPHIGOID MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 219. NATO BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. NATO BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 221. NATO BULLOUS PEMPHIGOID MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 222. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA BULLOUS PEMPHIGOID MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 234. CHINA BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 235. CHINA BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 236. CHINA BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 237. CHINA BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA BULLOUS PEMPHIGOID MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA BULLOUS PEMPHIGOID MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)